These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26824527)

  • 21. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
    Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Approaches to medical management of patients with high risk of progressing of benign prostatic hyperplasia depending on concomitant erectile dysfunction].
    Kamalov AA; Takhirzade AM
    Urologiia; 2018 Jul; (3):70-77. PubMed ID: 30035422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective study of clinical outcomes of α-blocker or finasteride monotherapy followed by combination therapy: determination of the period of combination therapy of α-blocker and finasteride.
    Son H; Cho SY; Park S; Kang JY; Kim CS; Kim HG
    Int J Clin Pract; 2013 Apr; 67(4):351-5. PubMed ID: 23521327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
    Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
    Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.
    Debruyne FM; Jardin A; Colloi D; Resel L; Witjes WP; Delauche-Cavallier MC; McCarthy C; Geffriaud-Ricouard C
    Eur Urol; 1998 Sep; 34(3):169-75. PubMed ID: 9732187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data.
    Fu Y; Han S; Wang L; Gao W; Wu E; Cao X; Wang J
    Adv Ther; 2018 Aug; 35(8):1191-1198. PubMed ID: 30014350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Dutasteride in Chinese Adults with Symptomatic Benign Prostatic Hyperplasia : A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Extension.
    Na Y; Ye Z; Zhang S
    Clin Drug Investig; 2012 Jan; 32(1):29-39. PubMed ID: 27933597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Combination drug therapy in patients with BPH].
    Kuzmenko AV; Kuzmenko VV; Gyaurgiev TA
    Urologiia; 2018 Mar; (1):101-105. PubMed ID: 29634142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy.
    Kuo HC; Liu HT
    Scand J Urol Nephrol; 2009; 43(3):206-11. PubMed ID: 19308807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
    Jin R; Forbes CM; Miller NL; Lafin J; Strand DW; Case T; Cates JM; Liu Q; Ramirez-Solano M; Mohler JL; Matusik RJ
    Prostate; 2024 Apr; 84(5):441-459. PubMed ID: 38168866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of prostatic-urethral angulation on the treatment outcome of patients with symptomatic benign prostatic hyperplasia treated with tamsulosin hydrochloride.
    El-Tatawy H; Gameel T; El-enen MA; Hagras A; Mousa A; El-Bahnasy AH; Raheem AA; Abu-dewan K
    Arch Ital Urol Androl; 2015 Sep; 87(3):238-42. PubMed ID: 26428648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia.
    Choi JD; Yoo TK; Kang JY; Jung HD; Lee JH
    Int Urol Nephrol; 2023 Apr; 55(4):845-851. PubMed ID: 36763223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study.
    Masumori N; Tsukamoto T; Horita H; Sunaoshi K; Tanaka Y; Takeyama K; Sato E; Miyao N
    Int J Urol; 2013 Apr; 20(4):421-8. PubMed ID: 22989348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy.
    Kurita Y; Masuda H; Suzuki K; Fujita K; Kawabe K
    Br J Urol; 1997 Jul; 80(1):78-83. PubMed ID: 9240185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder].
    Wada N; Hashidume K; Tamaki G; Kita M; Iwata T; Matsumoto S; Kakizaki H
    Hinyokika Kiyo; 2012 Sep; 58(9):475-80. PubMed ID: 23070385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial.
    Cai JL; Zhou Z; Yang Y; Yan YF; Jing S; Na YQ
    Chin Med J (Engl); 2016 Dec; 129(24):2899-2906. PubMed ID: 27958220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
    Trachtenberg J
    BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.